Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic alternatives.” ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose ...

A doctor may prescribe injectable treatments, such as methotrexate, TNF-alpha inhibitors, or interleukin inhibitors, for moderate to severe psoriasis when other treatments don’t work.

“For most patients who experienced anaphylaxis with glatiramer acetate use, the symptoms appeared within one hour of injection. In some cases, anaphylaxis resulted in hospitalization and death ...

That could soon change. Eisai, the company that makes Leqembi, said it asked the Food and Drug Administration (FDA) to approve a version of the drug that is given as a subcutaneous injection—a shot ...

At the centre of the dermatology market and within the interleukin inhibitor drug class, Sanofi takes a leading position with its blockbuster drug Dupixent (dupilumab), considered as the gold standard ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

The first biologic to enter the COPD market, Dupixent (dupilumab), has paved the way for competitors, demonstrating significant efficacy in reducing exacerbations. Dupixent’s success has highlighted ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

Sanofi’s chief executive Paul Hudson discussed the success of Dupixent (dupilumab)and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and ...